arrow
W

Winfried S. Wels

goethe university frankfurt hospital
H指数:61
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Local CAR-NK cell therapy in combination with systemic checkpoint inhibition induces anti-tumor responses even in distant tumor locations in an immunocompetent glioblastoma mouse model

局部CAR-NK细胞疗法与全身性检查点抑制相结合,即使在免疫健全的胶质母细胞瘤小鼠模型中的远端肿瘤部位也能诱导抗肿瘤反应。

2025-11-010
OAAI
CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma

CAR-NK细胞疗法与免疫检查点抑制相结合在胶质母细胞瘤中诱导了NKT细胞反应

2025-03-180
OA
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+rhabdomyosarcoma

Car-cik与car-t: 将新型细胞因子诱导的杀伤细胞作为ErbB2横纹肌肉瘤实体瘤免疫疗法的基准

2025-02-030
OAAI
MODULATION OF THE INTRATUMORAL IMMUNE MICROENVIRONMENT BY LOCAL THERAPY WITH NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中,通过用HER2-TARGETED嵌合抗原受体工程化的自然杀伤细胞局部治疗与全身ANTI-PD-1检查点抑制相结合来调节肿瘤内免疫微环境

2024-11-110
PRE
A REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中重复颅内注射单独使用HER2-TARGETED嵌合抗原受体并结合全身ANTI-PD-1检查点抑制的自然杀伤细胞

2024-10-170
PRE
Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies

使用物种交叉反应性NKG2D结合剂的双特异性杀伤细胞接合器将人和鼠淋巴细胞重定向至ErbB2/HER2-positive恶性肿瘤

2024-08-290
OAAI
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial

晚期肉瘤淋巴细胞清除后自体HER2-specific CAR T细胞: 1期临床试验

2024-04-247
OA
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation

CAR介导的靶向NK细胞克服了ICAM-1下调引起的肿瘤免疫逃逸

2024-02-274
OAAI
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
2023-05-0631
OAAI